secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001171843-25-000193
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus reports ~$123M cash, plans imdusiran Phase 2b in H1 2025; reduces burn to $47-50M
--------------------------------------------------------------------------------

- Cash, equivalents & investments ~$123M as of Dec 31, 2024; 2024 net cash burn ~$65M; 2025 burn expected $47-50M.
- Plans placebo-controlled Phase 2b trial of imdusiran + interferon + NA in HBeAg-negative cHBV with HBsAg ≤1000 IU/mL in H1 2025; target N=170.
- IM-PROVE I Phase 2a showed 50% functional cure (3/6) in HBeAg-negative patients with baseline HBsAg <1000 IU/mL; 25% overall.
- AB-101 oral PD-L1 Phase 1a/1b Part 3 (28-day repeat doses) data expected in H1 2025; next steps determined after.
- LNP litigation: claim construction hearing for Pfizer/BioNTech on Dec 18, 2024; Moderna trial set for Sept 24, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184325000193/0001171843-25-000193-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184325000193/f8k_011325.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-000193

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer